A federal judge overseeing litigation over allegedly inadequate side effect warnings on Ozempic and similar drugs appointed eight firms to leadership roles on the plaintiffs’ committee.
Dozens of lawsuits have accused Ozempic and Wegovy maker Novo Nordisk AS, and other pharmaceutical companies making similar drugs, of downplaying severe gastrointestinal side effects associated with the drugs. Ozempic was originally formulated to be a diabetes drug that regulated blood sugar levels by slowing down the digestive system, but demand for it and similar drugs skyrocketed after they became known for also causing weight loss.
- Judge Gene E.K. Pratter of the US District ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.